Prudential Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Prudential Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$217K	Buy	70,660 +47,580	+206%	+$184K	﹤0.01%	2116
2025 Q4	$94.4K	Sell	23,080 -22,565	-49%	-$112K	﹤0.01%	2121
2025 Q3	$223K	Buy	45,645 +2,575	+6%	+$13.5K	﹤0.01%	2189
2025 Q2	$218K	Buy	43,070 +24,280	+129%	+$119K	﹤0.01%	2181
2025 Q1	$99.4K	Buy	18,790 +2,720	+17%	+$19.8K	﹤0.01%	2131
2024 Q4	$109K	Hold	16,070	–	–	﹤0.01%	2141
2024 Q3	$106K	Sell	16,070 -18,415	-53%	-$132K	﹤0.01%	2571
2024 Q2	$259K	Buy	34,485 +1,515	+5%	+$13.2K	﹤0.01%	2406
2024 Q1	$329K	Buy	+32,970	New	+$367K	﹤0.01%	2307

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial's RXRX Position: Q1 2026 in Review

Prudential Financial increased its Recursion Pharmaceuticals (RXRX) stake by 206% in Q1 2026, buying an estimated $184K and bringing the position to 70,660 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

Prudential Financial first reported a position in RXRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $329K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Prudential Financial held 70,660 shares of Recursion Pharmaceuticals worth $217K as of Q1 2026.
Prudential Financial bought 47,580 Recursion Pharmaceuticals shares in Q1 2026, an estimated $184K.
Recursion Pharmaceuticals made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2116 holding.
Prudential Financial first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Prudential Financial's Recursion Pharmaceuticals position peaked at $329K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.